Sue Bruhn

Sue Bruhn

Company: Tiaki Therapeutics

Job title: Chief Executive Officer & President


Development of Targets Identified from Patients & Validated With Ex Vivo & In Vivo Models of Neuroinflammation 9:00 am

How can we best validate neuroinflammatory targets identified in patients? What are the key requirements to re-create the complex cellular microenvironment essential to study microglia function? What are the best translational tools for studying neuroinflammation?Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.